168 related articles for article (PubMed ID: 1012347)
1. Pharmacokinetics of spironolactone in man.
Abshagen U; Rennekamp H; Luszpinski G
Naunyn Schmiedebergs Arch Pharmacol; 1976 Dec; 296(1):37-45. PubMed ID: 1012347
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone. I. Disposition and metabolism.
Karim A; Zagarella J; Hribar J; Dooley M
Clin Pharmacol Ther; 1976 Feb; 19(2):158-69. PubMed ID: 1261153
[TBL] [Abstract][Full Text] [Related]
3. Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment.
Abshagen U; Rennekamp H; Luszpinski G
Eur J Clin Pharmacol; 1977 Mar; 11(3):169-76. PubMed ID: 856602
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.
Karim A; Hribar J; Aksamit W; Doherty M; Chinn LJ
Drug Metab Dispos; 1975; 3(6):467-78. PubMed ID: 1221
[TBL] [Abstract][Full Text] [Related]
5. Effects of pretreatment with spironolactone of pharmacokinetics of 4'''-methyldigoxin in man.
Abshagen U; Rennekamp H; Kuhlmann J
Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):87-92. PubMed ID: 934358
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
Vergin H; Nuss U; Strobel K
Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
[TBL] [Abstract][Full Text] [Related]
7. Isolation and identification of a sulfur-containing metabolite of spironolactone from human urine.
Koch K; Senn M; Steingross W
Steroids; 1976 Oct; 28(4):467-80. PubMed ID: 1006719
[TBL] [Abstract][Full Text] [Related]
8. Species differences in the metabolism and disposition of spironolactone.
Karim A; Kook C; Zitzewitz DJ; Zagarella J; Doherty M; Campion J
Drug Metab Dispos; 1976; 4(6):547-55. PubMed ID: 11976
[TBL] [Abstract][Full Text] [Related]
9. New insights into the pharmacokinetics of spironolactone.
Overdiek HW; Hermens WA; Merkus FW
Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
Krause W; Karras J; Seifert W
Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
[TBL] [Abstract][Full Text] [Related]
11. Influence of spironolactone pretreatment on pharmacokinetics and metabolism of digitoxin in rats.
VOHRINGER HF; Weller L; Rietbrock N
Naunyn Schmiedebergs Arch Pharmacol; 1975; 287(2):129-39. PubMed ID: 1143356
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
Ho PC; Bourne DW; Triggs EJ; Heazlewood V
Eur J Clin Pharmacol; 1984; 27(4):441-6. PubMed ID: 6519151
[TBL] [Abstract][Full Text] [Related]
13. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of spironolactone and potassium canrenoate in humans.
Kojima K; Yamamoto K; Fujioka H; Kaneko H
J Pharmacobiodyn; 1985 Mar; 8(3):161-6. PubMed ID: 4009408
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone. II. Bioavailability.
Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
[TBL] [Abstract][Full Text] [Related]
17. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.
Sadée W; Abshagen U; Finn C; Rietbrock N
Naunyn Schmiedebergs Arch Pharmacol; 1974; 283(3):303-18. PubMed ID: 4276758
[No Abstract] [Full Text] [Related]
18. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, enterohepatic circulation and biotransformation of [2-3H]-9,9-Dimethylacridane-10-carboxylic acid S-(2-dimethylamino) thiolethyl ester in the rat and dog.
Farrier DS
Arzneimittelforschung; 1977; 27(3):575-83. PubMed ID: 577424
[TBL] [Abstract][Full Text] [Related]
20. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
Bartle WR; Coates PE; Fisher MM; Louman FJ
Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
